• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Appeals court backs BSX over Cordis | Legal Roundup

Appeals court backs BSX over Cordis | Legal Roundup

June 8, 2011 By MassDevice staff

Stent Wars

A federal appeals court ruled that a quartet of patents owned by Johnson & Johnson (NYSE:JNJ) stent maker Cordis Corp. are invalid in a lawsuit between the healthcare giant and Boston Scientific Corp. (NYSE:BSX).

The patents in question are at the heart of complicated legal wrangling involving the Natick, Mass.-based medical device giant, its new Brunswick, N.J.-based rival, Abbott (NYSE:ABT) and Wyeth. The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the Cordis Cypher.

In January, Judge Susan Robinson of the U.S. District Court for Delaware ruled in favor of Boston Scientific‘s claim that J&J’s patent covering the sirolimus (also called rapamycin) used in the Cordis Cypher stent doesn’t cover the everolimus drug BSX uses in the Promus device. Everolimus is made by modifying the sirolimus molecule at a single location.

Robinson also found that the fourth patent wasn’t specific enough in describing exactly which drug formulations it covered to be valid, because the patent didn’t include a written description of at least one example of such a formulation.

Read more about the Stent Wars on MassDevice.com

The U.S. Court of Appeals for the Federal Circuit upheld Robinson’s decision yesterday.

"Because no finder of fact could reasonably determine that the asserted claims of the patents-in-suit contained an adequate written description, we affirm," wrote Judge Kimberley Moore, according to court documents. "We agree with BSC that no reasonable jury could conclude that there is sufficient written description support for the asserted claims of the 1997 patents."

Boston Scientific was quick to tout the win in a press release yesterday.

"We are pleased with the Court’s confirmation that all four Johnson & Johnson patents are invalid," Hank Kucheman, president of BSX’s cardiology, rhythm and vascular division, said in prepared remarks. "Boston Scientific will continue to vigorously defend against charges of infringement so that we can continue to provide our Promus products to patients in the U.S."

Cordis was more circumspect in a email to MassDevice.com.

"We are studying the ruling by the U.S. Court of Appeals for the Federal Circuit and have no comment at this time," wrote spokeswoman Sandy Pound.

The appeals court’s ruling is not the last word in the long-running stents war between Johnson & Johnson and Boston Scientific, which agreed to pay Cordis $716 million in September 2009 to settle 14 stent patent infringement suits. The settled cases, involving lawsuits in U.S., Canadian, Belgian, German, French and Italian courts, include the so-called Palmaz-NIR suit, involving a patent by the radiologist who invented stents, Julio Palmaz. The estimated settlement cost in that case would make up most of the $716 million nut to settle it and the other 13 suits. Johnson & Johnson owns that patent and in 2000 won a lawsuit alleging that an early BoSci stent, the NIR, infringed the technology. Boston Scientific appealed, but told investors in 2008 that it expected that case to cost at least $703 million.

And the company took a time-out from the tsuris over CEO Ray Elliott’s retirement to crow over a $19.5 million jury award in another case before Delaware’s Robinson (who ruled that separate juries would consider the penalty phases back in 2009).

gavel

Legal Roundup

Covidien counter-sues Applied Medical Resources
Covidien plc (NYSE:COV) counter-sued Applied Medical Resources Corp. for patent misuse, non-infringement and invalidity, two weeks after AMRC filed its fifth lawsuit over surgical trocars.

In May, Applied sued over a recently re-issued trocar patent. In its counter-suit, Covidien denies the patent infringement claim, according to a press release.

"The reissue patent is based on U.S. Patent 5,407,433 which was previously invalidated when a federal court granted a motion for summary judgment by a Covidien affiliate," according to the release. "This is the fifth time since 2003 that Applied has alleged patent infringement against a Covidien trocar product. Covidien has won the previous four cases. During that time, Covidien also won a jury verdict against Applied, finding that certain of Applied’s Kii and Universal trocars infringed a Covidien patent."

Last year, a federal judge ruled in favor of a Covidien patent infringement lawsuit, costing Applied Medical $4.8 million. That suit also involved a trocar, a device used for withdrawing fluids from a body cavity.
Read more

GOP leaders: Patent reform bill would make USPTO too powerful
Appropriations Committee chairman Rep. Hal Rogers (R-Ky.) and Budget Committee chairman Rep. Paul Ryan (R-Wis.) are demanding changes to a patent reform bill that’s been in the works in Washington for about half a decade.

"We strongly oppose this proposed shift of billions in discretionary funding and fee collections to mandatory spending," Rogers and Ryan wrote, according to Politico. "Putting PTO funding on auto-pilot is a move in exactly the wrong direction, given the new Republican majority’s commitment to restrained spending, improving accountability and transparency, and reducing the nation’s unparalleled deficits and debt."
Read more

Fed. Circ.: No en banc hearing in Siemens/St. Gobain spat

The U.S. Court of Appeals for the Federal Circuit denied a move by Saint Gobain SA (EPA:SGO) for an en banc review of the court’s decision to uphold a $45 million judgment against it for violating Siemens AG (ETR:SIE) patents covering medical imaging technology.
Read more

Filed Under: Legal News, News Well, Patent Infringement Tagged With: Abbott, Applied Medical Resources Corp., Boston Scientific, Cordis Corp., Covidien, Johnson and Johnson, Saint-Gobain, Siemens, Stent Wars, Wyeth

In case you missed it

  • House committee investigates $70M federal contract for AutoMedx ventilators
  • Edwards Lifesciences misses on earnings in Q4
  • COVID-19 assays sales power Hologic to Street-beating Q1
  • Stryker beats the Street on earnings but misses on revenue in Q4
  • How CGMs can inspire lifestyle changes
  • Johnson & Johnson gearing up for COVID-19 vaccine data announcement
  • Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer
  • Adapting to Pharma’s Next Normal – 2021 Pharmaceutical Trends
  • COVID-19 test sales boost Abbott in Street-beating Q4
  • Varian posts mixed bag Q1 results, expects Siemens Healthineers takeover to complete in early 2021
  • BD touts study of antigen test over molecular test for identifying infectious COVID-19 cases
  • Titan Medical closes on $11.5M offering
  • GE ticks up on mixed-bag Q4
  • BD CEO Polen to also serve as board chair
  • Moderna details ‘proactive’ strategy to fight emerging COVID-19 variants  
  • Surmodics’ DCB shown non-inferior to Medtronic’s In.Pact Admiral
  • Longeviti Neuro Solutions ClearFit implant wins FDA clearance for use in ultrasound

RSS From Medical Design & Outsourcing

  • House committee investigates $70M federal contract for AutoMedx ventilators
    A Congressional committee has launched an investigation into a $70 million White House contract for ventilators that reportedly are inadequate to treat people with COVID-19. The Department of Defense signed a $16.2 million contract in spring 2020 to buy SAVe II ventilators, manufactured by AutoMedx (Addison, Tex.), from the supplier Combat Medical Systems, according to… […]
  • How CGMs can inspire lifestyle changes
    As an early adopter of fitness trackers such as the Fitbit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic. I had heard about the potential of such technology… […]
  • COVID-19 mask factory opens in N.J.
    Hudson Holdings Group today announced it has opened a factory to make up to tens of millions of protective masks a month. The Piscataway, N.J., site will produce more than 200 jobs, according to the company, which is in partnership on the project with the State of New Jersey. “Our ultimate goal is to help,”… […]
  • TE Connectivity posts Street-beating Q1 results, medical sales dip 12%
    TE Connectivity (NYSE:TEL) posted first-quarter results today that beat the consensus on Wall Street. The Schaffhausen, Switzerland-based company reported profits of $381 million, or $1.13 per share, on sales of $3.5 billion for the three months ended Dec. 31, 2020, for a bottom-line gain of 1365.4% sales growth of 11.2% compared with Q1 2020. Adjusted to… […]
  • Could this 3-D printed ‘biomesh’ minimize hernia repair complications?
    Some hernia mesh implants have been associated with adverse post-surgical complications. So researchers at Baylor College of Medicine have developed a 3D-printed biomesh to support and reinforce the damaged abdominal wall and facilitate the healing process. Mesh implants may fail because they promote the adhesion of the intestine, liver or other visceral organs to the… […]
  • Superior Sensor Technology launches versatile differential pressure sensors
    Superior Sensor Technology (Santa Clara, Calif.) today announced the launch of differential pressure sensors for industrial applications that support up to seven selectable pressure ranges in one device. Designed for a wide range of applications, the new ND Series sensors support pressure ranges as low as 62.5 Pa/0.25” H2O to as high as 345 mBar/5… […]
  • BD touts study of antigen test over molecular test for identifying infectious COVID-19 cases
    Becton Dickinson (BD) is touting the results of a small, in-house study of its Veritor Plus antigen test over molecular (PCR) tests to indicate whether an infected person is more likely able to spread SARS-CoV-2. The peer-reviewed study compared antigen and PCR test results to positive results using a viral cell culture test. Viral growth… […]
  • TDK adds pressure sensors for ventilators
    TDK Corporation announced the launch of a new range of differential pressure sensors designed as printed circuit boards for use in medical devices. The sensors are designed for measurement ranges of 16 mbar full-scale (FS), 100 mbar FS and 7 bar FS, with accuracy of up to ±1% FS at temperatures from -20 °C to… […]
  • Pediatric device workshop scheduled for February
    A virtual public meeting on pediatric medical device development is scheduled for Feb. 9-11, 2021. Sponsors include the FDA, AdvaMed, the American Academy of Pediatrics and the Critical Path Institute, a public-private partnership that receives FDA funding. The System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) Virtual Workshop will focus on the… […]
  • Pedra wins breakthrough nod for perfusion system
    Singapore-based Pedra Technology announced today that the FDA has granted the company breakthrough device designation for the periprocedural use of its Xauron perfusion system in the treatment of critical limb-threatening ischemia (CLTI). CLTI is a severe form of peripheral artery disease (PAD) that is defined as ischemic rest pain, tissue loss or gangrene (tissue death) that… […]
  • Freudenberg Medical expands U.S. molding operations
    Freudenberg Medical announced that it has expanded injection molding operations at its Baldwin Park, Calif., operation, which is focused on thermoplastics. Freudenberg Medical Baldwin Park has added six injection molding machines including three new Arburg molding machines, a work cell for two-shot molding and a Wittmann Battenfeld micro-molding machine with in-process visual inspection capability. The… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS